GRAIL is trading at $139.40, up 5.16%, with broader-market strength providing context for the gain.
- Major indices are also higher.
- The weak September jobs report has eased rate-hike expectations, while Treasury yields are retreating.
- No fresh company-specific announcement was found for October 2. Reuters coverage discusses last week’s favorable FDA panel vote and an FDA decision expected in coming months.